BioSpace News Archive

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the full year ended December 31, 2022, and provided a corporate update.

NewAmsterdam Pharma Company N.V. today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will present at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 2:50 p.m. ET.

BeyondSpring Inc. today announced that the first patient has been enrolled in BeyondSpring’s Phase 2 investigator-initiated trial with lead asset, Plinabulin, in combination with Merck’s anti-PD-1 therapy Keytruda® (pembrolizumab) and Docetaxel for previously treated patients with metastatic non-small cell lung cancer (NSCLC) and progressive disease after immunotherapy (anti-PD-1 / PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy.

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, will report financial results for the full year ending December 31, 2022 on Wednesday, March 1, 2023 after the stock market close, and host a conference call on Thursday, March 2, 2023 at approximately 9:00 a.m. EST.

ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced a collaboration with mProbe, Inc. (“mProbe”), a precision health and medicine company utilizing clinical proteomics in the oncology space, and Dr. Christopher Hartley of Mayo Clinic for the continued development of its BE-Smart Esophageal Pre-Cancer Diagnostic Screening test.

Eli Lilly and Company announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of five new members to its Gene Therapy Scientific Advisory Board (SAB).

Epitomee, a biomedical company that develops unique ingestible therapeutic platforms for deployment of targeted therapies along the GI tract, and Nestlé Health Science, announced today that the patient enrollment for the Epitomee pivotal study has been finalized.

Strand Therapeutics today announced the appointment of Jay Stella, MBA as Chief Business Officer.

Thymmune Therapeutics, a biotechnology company developing scalable thymic cell therapies to restore immune function in aging and disease, announced today that it has secured $7 million in seed financing led by Pillar VC, with participation from NYBC Ventures and other investors.